Clareo Health | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
W8M-MC-LAA2
Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²)
Have Type 2 Diabetes
Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening
W8M-MC-CWMM:
Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)
You may not be if
W8M-MC-LAA2
Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
Have an on-going or history of bradyarrhythmia and/or sinus bradycardia
Have an elevated resting pulse rate (mean \>100 beats per minute (bpm)) or reduced resting pulse rate (mean \<60 bpm) at screening
Have any of the following cardiovascular conditions within 6 months prior to screening:
* acute myocardial infarction
* cerebrovascular accident (stroke)
* unstable angina, or
* hospitalization due to congestive heart failure
Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<45 milliliters per minute (mL/min)/1.73 m2
Have a history of acute or chronic pancreatitis
Have fasting triglycerides \>500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening
All concomitant medications should be at a stable dose for at least 3 months prior to screening
W8M-MC-CWMM
Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening.
Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
Have poorly controlled hypertension.
Have a history of symptomatic gallbladder disease within the past 2 years
Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
